WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS

This group comprises preparations used in the treatment of epilepsy.
Combined preparations are classified at separate 5th levels using the corresponding 50-series.
The group is subdivided according to chemical structure.

The DDDs for the antiepileptics are based on combination therapy.


N03AA Barbiturates and derivatives

Barbiturates used mainly as hypnotics/sedatives are classified in N05C - Hypnotics and sedatives.
Phenobarbital, which is used both as an antiepileptic and as a sedative, is classified in this group.
Combinations with phenytoin are classified in N03AB.

N03AB Hydantoin derivatives

Combinations of phenytoin and barbiturates are classified in this group.

N03AC Oxazolidine derivatives
N03AD Succinimide derivatives
N03AE Benzodiazepine derivatives

Clonazepam is classified in this group.
All other benzodiazepines are classified as anxiolytics in N05B (e.g. diazepam) or hypnotics/sedatives in N05C (e.g. midazolam).

N03AF Carboxamide derivatives
N03AG Fatty acid derivatives
N03AX Other antiepileptics

This group comprises antiepileptics, which cannot be classified in the preceding groups.
Fenfluramine indicated for the treatment of seizures associated with Dravet syndrome is classified here.
Gabapentin and pregabalin are classified in N02BF Gabapentinoids.

The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.

Last updated: 2024-01-26